Related Experiment Videos
Spironolactone-induced agranulocytosis: a case report
Shu-Hwa Hsiao1, Yih-Jyh Lin, May-Ying Hsu
1Department of Pharmacy, National Cheng Kung University Hospital, Tainan, Taiwan.
The Kaohsiung Journal of Medical Sciences
|December 9, 2003
Summary
Spironolactone, a diuretic, can cause agranulocytosis, a severe drop in white blood cells. This case highlights the risk, even without concurrent furosemide use, emphasizing careful patient monitoring.
Area of Science:
- Pharmacology
- Hematology
- Hepatology
Background:
- Ascites management in liver cirrhosis and hepatocellular carcinoma often involves diuretics.
- Spironolactone is a commonly prescribed potassium-sparing diuretic for fluid retention.
Observation:
- A patient developed severe leukopenia and agranulocytosis after initiating spironolactone therapy.
- The patient's leukocyte count normalized upon discontinuation of spironolactone.
Findings:
- This case strongly suggests spironolactone as the causative agent for drug-induced agranulocytosis.
- The absence of furosemide differentiates this case from previously reported spironolactone-associated agranulocytosis.
Implications:
- Clinicians should consider spironolactone as a potential cause of agranulocytosis in patients presenting with neutropenia.
- Enhanced vigilance and monitoring of leukocyte counts are crucial during spironolactone treatment, particularly in vulnerable patient populations.